FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953670277> ?p ?o ?g. }

• W2953670277 endingPage "1842" @default.
• W2953670277 startingPage "1842" @default.
• W2953670277 abstract "Abstract Introduction: Novel therapies have improved the median overall survival (OS) for newly diagnosed multiple myeloma (NDMM). In an unselected population of NDMM patients, the estimated rates of 5-year OS were 77%, 53%, and 19% for revised international staging system (R-ISS) Stage I, II, and III, respectively (Kastritis, 2017). However, the improvements have not been uniform, and prognosis varies considerably based on several baseline characteristics. Because of this clinical heterogeneity it is helpful to have a clear idea of risk factors involved in OS of patients with NDMM. Connect MM is the first and largest US-based, multicenter, prospective observational registry of patients with NDMM. Using data from the Connect MM registry, an unselected patient population reflective of the heterogeneity seen in routine clinical practice, we developed a prognostic tool to identify factors predictive of 3- and 5-year OS. Methods: The Connect MM registry is designed to describe baseline characteristics, patterns of care, and outcomes for NDMM in clinical practice. Patients were enrolled in Cohort 1 (n = 1493) between Sept 2009 and Dec 2011. Enrollment for Cohort 2 (n = 1518) began Dec 2012 and was completed April 2016. Data cut-off was July 7, 2016. Multivariate analyses of patient- and disease-related characteristics were conducted using Cohort 1 data to identify key predictors of OS. A series of univariate Cox regression models were used to identify variables significantly associated with 3-year and 5-year OS in patients ≤75 years and >75 years, as 75 years was determined to be the most discriminating age cut point, using Connect MM data, in identifying independent factors significantly associated with 3-year and 5-year OS. Prediction matrices for OS were constructed from the Cox model. Models were evaluated using the concordance (C)-index, a goodness of fitness measure. Internal validation of the logistic model in predicting the probability of survival was performed on data from Cohort 1. External validation of the model was performed on data from Cohort 2 and the Celgene-sponsored randomized phase III NDMM trials, MM-015 (N = 459) and FIRST (N = 1623). Results: Characteristics associated with late survival identified by multivariate analyses (P Conclusions: This is the first assessment of long-term survival using data from the Connect MM patient registry. Our study highlighted factors known to impact OS, including, mobility, del(17p) and ISS stage. We have developed a model that allows for robust prediction of long-term survival in patients with NDMM based on a variety of baseline characteristics. For clinicians, identifying patients with an increased likelihood of longer survival may be a useful tool to identify patient specific risk factors to better inform treatment decisions. Download : Download high-res image (467KB) Download : Download full-size image Disclosures Terebelo: Celgene: Consultancy; Janssen: Speakers Bureau; Takeda: Speakers Bureau; Pharmacyclics: Speakers Bureau. Abonour: Celgene: Other: Steering committee, Research Funding; Takeda: Other: Steering committee, Research Funding; Prothena: Research Funding. Gasparetto: Janssen, BMS, Celgene, Takeda: Honoraria; Janssen, BMS, Celgene: Other: Travel, accommodations, or other expenses paid or reimbursed; Celgene: Research Funding; Janssen, BMS, Celgene: Consultancy. Toomey: Celgene: Consultancy; Myriad Genetics: Speakers Bureau; Dava Oncology: Other: Travel. Durie: Takeda: Consultancy; Janssen: Consultancy. Hardin: Celgene: Consultancy. Jagannath: Celgene: Consultancy; Merck: Consultancy; Novartis: Consultancy; Bristol-Meyers Squibb: Consultancy; Medicom: Speakers Bureau; MMRF: Speakers Bureau. Wagner: EveryFit: Consultancy; Gilead: Consultancy; Janssen: Consultancy. Narang: Celgene: Consultancy, Speakers Bureau; Janssen: Speakers Bureau. Srinivasan: Celgene: Employment. Yue: Celgene: Employment. Zafar: Celgene: Employment. Kitali: Celgene: Employment. Agarwal: Celgene Corporation: Employment. Rifkin: Amgen: Consultancy; Boehringer Ingelheim: Consultancy; Celgene: Consultancy; EMD Serono: Consultancy; Sandoz: Consultancy; Takeda: Consultancy; McKesson: Other: Stock." @default.
• W2953670277 created "2019-07-12" @default.
• W2953670277 creator A5018302007 @default.
• W2953670277 creator A5026109406 @default.
• W2953670277 creator A5028046297 @default.
• W2953670277 creator A5028248272 @default.
• W2953670277 creator A5041503485 @default.
• W2953670277 creator A5043351209 @default.
• W2953670277 creator A5044273966 @default.
• W2953670277 creator A5047486042 @default.
• W2953670277 creator A5051117077 @default.
• W2953670277 creator A5059616971 @default.
• W2953670277 creator A5060516816 @default.
• W2953670277 creator A5064115439 @default.
• W2953670277 creator A5066180365 @default.
• W2953670277 creator A5068510673 @default.
• W2953670277 creator A5079064611 @default.
• W2953670277 date "2017-12-07" @default.
• W2953670277 modified "2023-09-28" @default.
• W2953670277 title "Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect® MM Patient Registry" @default.
• W2953670277 doi "https://doi.org/10.1182/blood.v130.suppl_1.1842.1842" @default.
• W2953670277 hasPublicationYear "2017" @default.
• W2953670277 type Work @default.
• W2953670277 sameAs 2953670277 @default.
• W2953670277 citedByCount "0" @default.
• W2953670277 crossrefType "journal-article" @default.
• W2953670277 hasAuthorship W2953670277A5018302007 @default.
• W2953670277 hasAuthorship W2953670277A5026109406 @default.
• W2953670277 hasAuthorship W2953670277A5028046297 @default.
• W2953670277 hasAuthorship W2953670277A5028248272 @default.
• W2953670277 hasAuthorship W2953670277A5041503485 @default.
• W2953670277 hasAuthorship W2953670277A5043351209 @default.
• W2953670277 hasAuthorship W2953670277A5044273966 @default.
• W2953670277 hasAuthorship W2953670277A5047486042 @default.
• W2953670277 hasAuthorship W2953670277A5051117077 @default.
• W2953670277 hasAuthorship W2953670277A5059616971 @default.
• W2953670277 hasAuthorship W2953670277A5060516816 @default.
• W2953670277 hasAuthorship W2953670277A5064115439 @default.
• W2953670277 hasAuthorship W2953670277A5066180365 @default.
• W2953670277 hasAuthorship W2953670277A5068510673 @default.
• W2953670277 hasAuthorship W2953670277A5079064611 @default.
• W2953670277 hasConcept C105795698 @default.
• W2953670277 hasConcept C126322002 @default.
• W2953670277 hasConcept C144024400 @default.
• W2953670277 hasConcept C149923435 @default.
• W2953670277 hasConcept C151956035 @default.
• W2953670277 hasConcept C161584116 @default.
• W2953670277 hasConcept C199163554 @default.
• W2953670277 hasConcept C201903717 @default.
• W2953670277 hasConcept C23131810 @default.
• W2953670277 hasConcept C2776364478 @default.
• W2953670277 hasConcept C2778959093 @default.
• W2953670277 hasConcept C2779134260 @default.
• W2953670277 hasConcept C2908647359 @default.
• W2953670277 hasConcept C33923547 @default.
• W2953670277 hasConcept C38180746 @default.
• W2953670277 hasConcept C50382708 @default.
• W2953670277 hasConcept C71924100 @default.
• W2953670277 hasConcept C72563966 @default.
• W2953670277 hasConcept C99454951 @default.
• W2953670277 hasConceptScore W2953670277C105795698 @default.
• W2953670277 hasConceptScore W2953670277C126322002 @default.
• W2953670277 hasConceptScore W2953670277C144024400 @default.
• W2953670277 hasConceptScore W2953670277C149923435 @default.
• W2953670277 hasConceptScore W2953670277C151956035 @default.
• W2953670277 hasConceptScore W2953670277C161584116 @default.
• W2953670277 hasConceptScore W2953670277C199163554 @default.
• W2953670277 hasConceptScore W2953670277C201903717 @default.
• W2953670277 hasConceptScore W2953670277C23131810 @default.
• W2953670277 hasConceptScore W2953670277C2776364478 @default.
• W2953670277 hasConceptScore W2953670277C2778959093 @default.
• W2953670277 hasConceptScore W2953670277C2779134260 @default.
• W2953670277 hasConceptScore W2953670277C2908647359 @default.
• W2953670277 hasConceptScore W2953670277C33923547 @default.
• W2953670277 hasConceptScore W2953670277C38180746 @default.
• W2953670277 hasConceptScore W2953670277C50382708 @default.
• W2953670277 hasConceptScore W2953670277C71924100 @default.
• W2953670277 hasConceptScore W2953670277C72563966 @default.
• W2953670277 hasConceptScore W2953670277C99454951 @default.
• W2953670277 hasLocation W29536702771 @default.
• W2953670277 hasOpenAccess W2953670277 @default.
• W2953670277 hasPrimaryLocation W29536702771 @default.
• W2953670277 hasRelatedWork W1600579707 @default.
• W2953670277 hasRelatedWork W2324333179 @default.
• W2953670277 hasRelatedWork W2412090675 @default.
• W2953670277 hasRelatedWork W2520449616 @default.
• W2953670277 hasRelatedWork W2554687131 @default.
• W2953670277 hasRelatedWork W2558033492 @default.
• W2953670277 hasRelatedWork W2584611162 @default.
• W2953670277 hasRelatedWork W2589125869 @default.
• W2953670277 hasRelatedWork W2593806361 @default.
• W2953670277 hasRelatedWork W2917684629 @default.
• W2953670277 hasRelatedWork W2968943708 @default.
• W2953670277 hasRelatedWork W2981854025 @default.
• W2953670277 hasRelatedWork W2984487287 @default.
• W2953670277 hasRelatedWork W2989331680 @default.
• W2953670277 hasRelatedWork W3033702078 @default.
• W2953670277 hasRelatedWork W3102788739 @default.

• next